FDA Brief

Warning letters Drugs

FDA warning letter to

Yahon Enterprise Co., Ltd.

High riskIssued Jun 5, 2024Posted Jul 23, 2024Center for Drug Evaluation and Research (CDER)

FDA warned Yahon Enterprise over manufacturing quality failures for OTC antiseptic wipes after a December 2023 inspection.

What happened

FDA inspected the Vietnam drug manufacturing facility from December 15 to 21, 2023. It found that Yahon released OTC ethyl alcohol antiseptic wipes without testing each batch for identity and strength of the active ingredient, did not adequately test incoming ethyl alcohol and benzalkonium chloride, and set a three-year expiry without stability data.

What FDA found

  1. Yahon released OTC drug products, including ethyl alcohol antiseptic wipes, without adequate testing of each batch for identity and strength of the active ingredient before release.

    21 CFR 211.165(a)
  2. Yahon did not perform adequate identity testing on each lot of ethyl alcohol and benzalkonium chloride used to make its OTC drugs.

    21 CFR 211.84(d)(2)
  3. Yahon assigned a three-year expiration date to ethyl alcohol antiseptic wipes without stability data to support it.

    21 CFR 211.137(a)
  4. Yahon’s quality unit did not ensure adequate process validation, cleaning validation, required manufacturing record storage, or reserve sample collection and storage.

    21 CFR 211.22

What FDA wants

FDA tells Yahon to respond in writing within 15 working days with what it has done to correct the violations and prevent recurrence, and to state reasons and a completion schedule if it cannot finish. FDA also recommends engaging a qualified CGMP (current good manufacturing practice) consultant.

Who should pay attention

  • U.S. distributors and retailers selling Yahon antiseptic wipes
  • brands that rely on contract manufacturers for OTC drugs
  • quality teams managing supplier qualification and component testing

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Shenzhen Benliju Biotech Co., Ltd.

    FDA: Shenzhen Benliju Biotech released OTC drugs labeled sterile without sterility testing or process validation.

    High risk
  3. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  4. Penn Herb Company, Ltd.

    FDA warned Penn Herb Company over CGMP violations and an undeclared tree-nut allergen in three dietary supplements.

    High risk